The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.